Home News
News
GlaxoSmithKline (GSK) and Pfizer are holding out for an improved bid of at least £60 billion (US$82 billion) for their consumer healthcare joint venture, bolstered by shareholder opposition to Unilever’s £50 billion (US$68.4 billion) offer, reported The Financial Times.
GSK dismissed Unilever’s bid on Saturday, January...
More Top Stories
GlaxoSmithKline & Pfizer Are Holding Out For Higher Bid In Joint Venture
GlaxoSmithKline (GSK) and Pfizer are holding out for an improved bid of at least £60 billion (US$82 billion) for their consumer healthcare joint venture,...
State AGs Appeal Dismissal Of Facebook Antitrust Case
Nearly four dozen states on Friday, January 14, asked a federal appeals court to reconsider an antitrust lawsuit against Facebook that a judge threw...
EU’s Vestager Questions Gazprom Over Price Hikes
The European Union's antitrust chief said she had asked gas companies, including Gazprom, about tight supplies after accusations the Russian giant was holding back...
AMC Entertainment Wins Collusion Suit
Movie theater chain AMC Entertainment won an antitrust case brought by iPic-Gold Class Entertainment, alleging AMC had conspired with another movie theater to keep...
Judge Narrows Antitrust Case Against Teva Over Gilead HIV Drugs
Teva Pharmaceutical Industries succeeded in scaling back its potential antitrust exposure for allegedly helping delay generic versions of Gilead Sciences's blockbuster HIV drugs, when...
Benoît Cœuré To Lead French Competition Authority
Benoît Cœuré has been named as the new head of the Autorité de la Concurrence (ADLC), France’s competition regulator.
In sessions on January 12, both...
Apple Complies With Dutch Watchdog Over Payment Options
Apple stated on Saturday, January 15, it would allow developers of dating apps in the Netherlands to offer non-Apple payment options to their users,...
